For individuals living with chronic conditions, stable housing enables consistent care. Conversely, housing instability can disrupt care continuity, increase financial strain, and contribute to ...

Capital Rx is now Judi Rx, maintaining a transparent pass-through PBM model while aligning brand architecture with the Judi ...

Symptom-based liver enzyme and triglyceride testing is proposed for isotretinoin patients without risk factors to reduce ...

Ambient-stable microneedle patches are positioned as a route to reduce refrigeration dependence and simplify administration ...

There will be a greater focus on surgical topics at the 2025 meeting of the American Society of Retina Specialists, compared with previous years, which reflects the need for balan ...

Despite advancements in vaccination and treatment, COVID-19 was responsible for 1.8% of all deaths in the United States during the week of January 4-11, 2025. 1-3 The virus disproportionately affects ...

Dismissals occurred in 432 of 174,250 patients (0.25%), with noncompliance (60.2%) and aggressive or inappropriate conduct (18.2%) comprising the majority of cited reasons. Demographic differences ...

Bevacizumab reached 29.8% of 2025 injections, rising from 23.3% in 2024, while aflibercept 2 mg fell to 21.9% from 36.9% in 2024. Reduced Good Days copay assistance disrupted affordability for branded ...

Retrospective Cleveland Clinic data (89 eyes) linked branded-to-bevacizumab switching with increased CST, shortened median injection interval (8.6 to 7.5 weeks), and 15.7% meeting poor-outcome ...

FDA authorization positions enlicitide as the first oral PCSK9 inhibitor, targeting PCSK9–LDLR interaction via macrocyclic peptide binding to deliver substantial LDL-C lowering in a daily pill ...

Preoperative statin exposure correlated with substantially reduced PVR incidence, the principal driver of rhegmatogenous retinal detachment repair failure, suggesting a potentially modifiable ...

IQVIA projects 118 U.S. biologics losing exclusivity by 2034 (~$234B opportunity), but only 12 had biosimilars in development as of Sept 2024, leaving most molecules uncontested. FDA draft guidance ...